Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer.

ABSTRACT:

Importance

Immune checkpoint inhibitors (ICIs) have been approved for treatment of microsatellite instable (MSI-H) metastatic colorectal cancer (mCRC), but factors associated with receipt and efficacy of ICIs in routine clinical practice remain largely unknown.

Objective

To identify factors associated with receipt of ICIs and associated survival outcomes among patients with mCRC in routine clinical practice.

Design, setting, and participants

This population-based cohort study used deidentified data from a nationwide electronic health record-derived database to include 18 932 patients diagnosed with mCRC between January 2013 and June 2019. Population-based patients were diagnosed with de novo mCRC and had at least 2 documented clinical visits on or after the date of di

SUBMITTER: Bari S 

PROVIDER: S-EPMC11926646 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature